The Promise and Challenges of Cyclic Dinucleotides as Molecular Adjuvants for Vaccine Development

Vaccines (Basel). 2021 Aug 17;9(8):917. doi: 10.3390/vaccines9080917.

Abstract

Cyclic dinucleotides (CDNs), originally discovered as bacterial second messengers, play critical roles in bacterial signal transduction, cellular processes, biofilm formation, and virulence. The finding that CDNs can trigger the innate immune response in eukaryotic cells through the stimulator of interferon genes (STING) signalling pathway has prompted the extensive research and development of CDNs as potential immunostimulators and novel molecular adjuvants for induction of systemic and mucosal innate and adaptive immune responses. In this review, we summarize the chemical structure, biosynthesis regulation, and the role of CDNs in enhancing the crosstalk between host innate and adaptive immune responses. We also discuss the strategies to improve the efficient delivery of CDNs and the recent advance and future challenges in the development of CDNs as potential adjuvants in prophylactic vaccines against infectious diseases and in therapeutic vaccines against cancers.

Keywords: bacterial second messenger; c-di-GMP; cyclic dinucleotide; immunostimulation; vaccine adjuvant.

Publication types

  • Review